Skip to content

Opening book details…

About this Economics, Econometrics and Finance article

Cost-Effectiveness of Daclizumab Versus Interferon Beta-1A in the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in the United States by Rao, D; Heidari, E; Kamal, KM; Dashputre, AA is a Economics, Econometrics and Finance article available to read on EtoBox.

It is typically read by researchers, students, and practitioners in Economics, Econometrics and Finance.

Author
Rao, D; Heidari, E; Kamal, KM; Dashputre, AA
Publisher
John Wiley and Sons; Elsevier ; Elsevier Ltd.; Elsevier BV (ISSN 1098-3015)
Published
2018
Language
EN
Field
Economics, Econometrics and Finance (Social Sciences)

More by Rao, D; Heidari, E; Kamal, KM; Dashputre, AA

Browse all works by Rao, D; Heidari, E; Kamal, KM; Dashputre, AA